West Pharmaceutical Reiterates Growth Story at Morgan Stanley Conference; No New Data to Alter Valuation Debate

What happened

West Pharmaceutical Services presented at the Morgan Stanley Global Healthcare Conference on September 14, 2026, with management likely reiterating its strong HVP demand trends and full-year guidance provided in July. The presentation came after a strong Q2 that saw 12.7% organic growth and a raised outlook, but no new financial disclosures or strategic updates were provided in the published transcript. The DeepValue master report already reflects this operating momentum, noting HVP components grew 20.4% in H1 and gross margin expanded 200 bps, yet the stock trades at 42.9x P/E and 32.7x EV/EBITDA. With shares around $338, the valuation debate hinges on whether upcoming quarters prove the premium growth is durable, especially as Dublin commercialization and West Vantage recovery remain unquantified. The conference appearance reinforces the existing narrative but does not resolve the key uncertainties around oral GLP-1 substitution, peer capacity additions, and margin sustainability.

Implication

The Morgan Stanley presentation likely reiterated strength in HVP components and biologics demand, but without new data, the investment case is unchanged. The current valuation already assumes sustained HVP growth, stable injectable obesity mix, and smooth Dublin ramp, leaving little margin for error. Key checkpoints remain Q3 revenue within $820-835 million and gross margin above 37.5%, plus any explicit Dublin disclosure. Until those milestones are met, the stock's risk/reward is balanced, with attractive entry near $300 and trim territory above $365. A break below $320 on any signs of demand softening or margin pressure would signal a shift to a more cautious positioning.

Thesis delta

There is no thesis delta from this event. The conference presentation is consistent with the existing WAIT thesis and does not alter the assessment of valuation or operational trajectory. The key uncertainties—Dublin conversion, West Vantage recovery, oral GLP-1 risk—remain unresolved, so no change in conviction or price targets is warranted.